Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients.

ABSTRACT:

Background

Cancer patients are considered highly vulnerable to the COVID-19 pandemic. However, delaying cancer-specific therapies could have a deleterious effect on survival. The potential suppressive effects of chemotherapies or cancer-related microenvironment raised the question on how cancer patients' immune system responds to SARS-CoV-2 virus.

Methods

We have started a prospective monocentric trial entitled COV-CREM (NCT04365322) in April 2020. The primary objective of the trial was to assess specific immune response's intensity and diversity to SARS-CoV-2 in infected patients.

Results

In this study, we showed that cancer patients (28 solid tumours, 11 haematological malignancies) exposed to SARS-CoV-2 produced a high rate of specific antibodies, as observed in pa

SUBMITTER: Mansi L 

PROVIDER: S-EPMC7997727 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature